Skip to search formSkip to main contentSkip to account menu

ranibizumab Injection [Lucentis]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

0.05 ML ranibizumab 6 MG/ML Injection [Lucentis]
InjectionLucentis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
Purpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading… 
Review
2016
Review
2016
Lucentis® (ranibizumab ophthalmic injection) for diabetic macular edema (DME)
Objective: To review the efficacy, safety and pharmacologic parameters of ranibizumab (Lucentis®) intravitreal ophthalmic… 
2014
2014
REAL Study :Re-treatment Evaluated on visual Acuity for Lucentis°.
2013
2013
Bevacizumab und Ranibizumab bei Makulaödem bei retinalen Venenverschlüssen
Zusammenfassung Hintergrund: Den Effekt von Bevacizumab (BE)(Avastin®) und Ranibizumab (RA) (Lucentis®) auf die Sehschärfe (VA… 
2011
2011
Protein Drug Delivery and Formulation Development
Several therapeutic agents including low and high molecular weight drugs intended for treating back of the eye disorders are… 
2010
2010
Analysis of reading eye movements with Tobii 1750TM eye tracker in AMD patients pre and post op ranibizumab (LucentisTM) treatment
Purpose In age‐related macular degeneration (AMD), the main deficit is the loss of reading ability. The neovascular form of age… 
2010
2010
Frühzeitige Behandlung mit Ranibizumab (Lucentis®) bei exsudativer AMD
ZusammenfassungHintergrundMit der intravitrealen Applikation von Ranibizumab (Lucentis®) steht eine effektive Behandlungsm… 
2007
2007
Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
2006
2006
An Emerging Problem: Recurrence of CNV in AMD is Common After Cessation of 24 Month Treatment With Ranibizumab (Lucentis®)
2006
2006
Vascular Effects of Combined Ranibizumab (Lucentis®) and Verteporfin (Visudyne®) Therapy in Patients With Neovascular Age–Related Macular Degeneration
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)